Acorda Multiple Sclerosis Phase 3 Trial Shows Positive Results
Shares of Acorda Therapeutics (ACOR) are up more than 40% in pre-market action as the company announced that its phase 3 trial of Fampridine-SR showed positive results in improving walking in MS patients.
Previous studies have shown Fampridine-SR to improve communication between damaged neurons, the cells of the nervous system.
_
Shares of Acorda Therapeutics (ACOR) are up more than 40% in pre-market action as the company announced that its phase 3 trial of Fampridine-SR showed positive results in improving walking in MS patients.
Previous studies have shown Fampridine-SR to improve communication between damaged neurons, the cells of the nervous system.
_
posted by Nico at
7:59 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home